Eli Lilly has filed six new lawsuits against U.S. entities selling unapproved retatrutide, an investigational drug still in Phase 3 trials for obesity and diabetes. The company warns that black-market retatrutide is unsafe and illegal, urging regulators, social media platforms, and payment processors to help stop its distribution. Lilly has also reported thousands of illegal listings worldwide and called for coordinated global enforcement to protect patients from these dangerous products. This legal action highlights the growing concern over unregulated drug sales posing health risks to consumers.
Vanguard's VTSAX mutual fund, though low-cost on paper, can incur significant hidden expenses like capital gains taxes, a $3,000 minimum investment, and transaction fees outside Vanguard platforms. Its ETF counterpart, VTI, offers the same broad US m...
Wave Life Sciences shares are down significantly this year, trading near their 52-week low with a market cap around $1 billion. The company, focused on RNA-based medicines, holds substantial cash but is currently unprofitable. Its key assets include ...
Novo Nordisk CEO Mike Doustdar defended the company's lawsuit against Eli Lilly, accusing Lilly of misleading advertising about their weight-loss drug efficacy. Novo argues that Lilly's ads compare Lilly's Zepbound to an older, lower-dose version of ...
Eli Lilly reported strong sales growth for its drugs Mounjaro, Jaypirca, and Omvoh, with Jaypirca sales up 56.4% year-on-year to $192 million in Q2 despite competition. The company’s Retatrutide showed promising results in obesity trials, potentially...
Novo Nordisk CEO Mike Doustdar highlighted the early stage of GLP-1 drug adoption for obesity treatment, noting that over 100 million Americans suffer from obesity but only about 10-15% have used these medications. He emphasized the potential for the...
